Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of high-dose aflibercept for macular edema due to retinal vein occlusion
MOH_2023-09-03_012904Phase 3Completed
- Sponsor
- Bayer
- Start
- Aug 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aflibercept in Vein occlusion (RVO), sponsored by Bayer. Primary endpoint: Change in best corrected visual acuity. Started Aug 2023; status: completed.
02
Drugs
aflibercept
03
Conditions
Vein occlusion (RVO)
Beyond the preview
Go deeper on MOH_2023-09-03_012904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-09-03_012904.